meto
Log in
Peptide

Retatrutide

A next-generation triple agonist targeting GLP-1, GIP and glucagon receptors — the most effective weight-management peptide seen in phase-2 trials.

Definition

An investigational 39-amino-acid peptide that activates three incretin-related receptors simultaneously: GLP-1, GIP, and glucagon. The phase-2 TRIUMPH trial reported 24.2% weight loss at 48 weeks at the 12 mg dose — exceeding tirzepatide. It remains investigational in the US as of April 2026, with regulatory filings anticipated.

How Meto uses it.

Not currently dispensed at Meto. We track the retatrutide pipeline closely because the triple-agonist mechanism represents a genuine step change over dual-agonist tirzepatide. When FDA-approved, it will likely enter the platform as a third-line GLP-1-class option.

Safety notes

  • Investigational — not available for prescription in the US as of April 2026
  • Expected contraindications parallel semaglutide and tirzepatide (MTC, MEN 2, pancreatitis)
  • Phase-2 data shows GI side-effect profile similar to tirzepatide

Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.

Common questions

Can I get retatrutide from Meto today?

No. Retatrutide remains investigational in the US and is not available through any compounding pharmacy.

How does retatrutide compare to tirzepatide?

Phase-2 TRIUMPH showed ~24% weight loss at 48 weeks versus ~21% for tirzepatide in SURMOUNT-1 at 72 weeks.

PreviousResearch ChemicalSafetyNextSarcopeniaClinical Concept

Read More

Peptide

TirzepatideMounjaro

A dual GLP-1 and GIP receptor agonist — the most effective FDA-approved weight-management peptide to date, the active ingredient in Mounjaro and Zepbound.

Peptide

SemaglutideOzempic

A long-acting GLP-1 receptor agonist used for type-2 diabetes and chronic weight management — the active ingredient in Ozempic and Wegovy.

Peptide

GLP-1 Receptor AgonistGLP-1 RA

A peptide drug class that mimics glucagon-like peptide-1 to slow gastric emptying, sharpen insulin response and quiet food-noise.

$149 panel.
A clinician reads it in 24 hours.

Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.

Start with labs · $149